Lenvatinib.
出版信息
Aust Prescr. 2017 Dec;40(6):242-243. doi: 10.18773/austprescr.2017.070. Epub 2017 Oct 3.
Abstract
摘要
相似文献
1
Lenvatinib.乐伐替尼
Aust Prescr. 2017 Dec;40(6):242-243. doi: 10.18773/austprescr.2017.070. Epub 2017 Oct 3.
2
Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer.乐伐替尼增强了紫杉醇在间变性甲状腺癌中的抗肿瘤作用。
Am J Cancer Res. 2017 Apr 1;7(4):903-912. eCollection 2017.
3
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma.一名转移性乳头状甲状腺癌患者在初始使用乐伐替尼耐药后序贯使用索拉非尼，之后再次使用乐伐替尼进行治疗。
Case Rep Oncol. 2020 May 12;13(2):522-527. doi: 10.1159/000507344. eCollection 2020 May-Aug.
4
Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells.乐伐替尼通过增强自然杀伤细胞的肿瘤浸润和激活来促进抗肿瘤免疫。
Am J Cancer Res. 2019 Jul 1;9(7):1382-1395. eCollection 2019.
5
Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation.乐伐替尼与华法林钾联合治疗导致凝血酶原时间延长。
Hepatol Res. 2019 Nov;49(11):1357-1361. doi: 10.1111/hepr.13379. Epub 2019 Jul 10.
6
A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib.一例对多靶点酪氨酸激酶抑制剂乐伐替尼有反应的原发灶不明的鳞状细胞癌病例。
Case Rep Oncol. 2018 Feb 9;11(1):75-80. doi: 10.1159/000486569. eCollection 2018 Jan-Apr.
7
Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9*1/*3 and VKORC1-1639G/A genotype.患者 CYP2C9*1/*3 和 VKORC1-1639G/A 基因型时，华法林与仑伐替尼的药物相互作用。
J Clin Pharm Ther. 2019 Dec;44(6):977-980. doi: 10.1111/jcpt.13030. Epub 2019 Aug 30.
8
Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma.用于定量分析人血浆中乐伐替尼的液相色谱 - 串联质谱法的验证
Int J Anal Chem. 2017;2017:2341876. doi: 10.1155/2017/2341876. Epub 2017 Jun 7.
9
Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants.酮康唑对健康受试者中乐伐替尼（E7080）药代动力学的影响。
Clin Pharmacol Drug Dev. 2015 Mar;4(2):155-160. doi: 10.1002/cpdd.140. Epub 2014 Aug 28.
10
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events.周末停用乐伐替尼治疗不可切除肝细胞癌可改善治疗反应及对不良事件的耐受性。
Cancers (Basel). 2020 Apr 19;12(4):1010. doi: 10.3390/cancers12041010.
引用本文的文献
1
The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair.酪氨酸激酶抑制剂对伤口愈合和修复的不良影响。
Int Wound J. 2025 Apr;22(4):e70513. doi: 10.1111/iwj.70513.
2
Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone.抗血管生成酪氨酸激酶抑制剂在骨转移透明细胞肾细胞癌中的疗效有差异。
Cancer Res Commun. 2024 Oct 1;4(10):2621-2637. doi: 10.1158/2767-9764.CRC-24-0304.
3
Effects of Short-Term Lenvatinib Administration Prior to Transarterial Chemoembolization for Hepatocellular Carcinoma.肝癌经动脉化疗栓塞术前短期服用乐伐替尼的效果
Cancers (Basel). 2024 Apr 23;16(9):1624. doi: 10.3390/cancers16091624.
4
Efficacy of lenvatinib sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta-analysis.乐伐替尼与索拉非尼在晚期肝细胞癌一线治疗中的疗效：一项荟萃分析。
JGH Open. 2023 Dec 13;7(12):832-840. doi: 10.1002/jgh3.12999. eCollection 2023 Dec.
5
Lenvatinib as a Promising Treatment Option for Unresectable Hürthle Cell Carcinoma: A Case Report.乐伐替尼作为不可切除性许特耳细胞瘤的一种有前景的治疗选择：一例病例报告。
Cureus. 2023 Apr 11;15(4):e37460. doi: 10.7759/cureus.37460. eCollection 2023 Apr.
6
Immunotherapy-induced retinopathy mimicking cancer associated retinopathy.免疫疗法诱发的视网膜病变，酷似癌症相关性视网膜病变。
Am J Ophthalmol Case Rep. 2022 Mar 1;26:101449. doi: 10.1016/j.ajoc.2022.101449. eCollection 2022 Jun.
本文引用的文献
1
Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.仑伐替尼治疗放射性碘难治性分化型甲状腺癌：一项系统评价及与索拉非尼的间接比较
Expert Rev Anticancer Ther. 2016 Dec;16(12):1303-1309. doi: 10.1080/14737140.2016.1247697. Epub 2016 Oct 28.
2
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.仑伐替尼、依维莫司及二者联合用于转移性肾细胞癌患者的随机、Ⅱ期、开放标签、多中心试验。
Lancet Oncol. 2015 Nov;16(15):1473-1482. doi: 10.1016/S1470-2045(15)00290-9. Epub 2015 Oct 22.
3
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.乐伐替尼对比安慰剂用于碘难治性甲状腺癌。
N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470.
4
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.索拉非尼用于放射性碘难治性、局部晚期或转移性分化型甲状腺癌：一项随机、双盲、3期试验。
Lancet. 2014 Jul 26;384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24.
Zotero 插件